Advertisement

Topics

Bristol-Myers Squibb’s Opdivo Receives FDA Approval for Opdivo in Certain Patients with Advanced Colorectal Cancer

09:21 EDT 1 Aug 2017 | Speciality Pharma Journal

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and …

Original Article: Bristol-Myers Squibb’s Opdivo Receives FDA Approval for Opdivo in Certain Patients with Advanced Colorectal Cancer

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb’s Opdivo Receives FDA Approval for Opdivo in Certain Patients with Advanced Colorectal Cancer"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...